Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results